🔎 Trials Near Me

Hjem › Lupus › Texas › Houston

Lupus kliniske forsøg i Houston, TX

13 studier for Lupus søger deltagere på steder i og omkring Houston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

RekruttererFase 3
  • Sl0044 50696, Houston
  • Sl0044 50723, Houston
  • Sl0044 50738, Bellaire · 7 mi væk
Alder 16 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06617325

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

RekruttererFase 2
  • Prolato Clinical Research Center, Houston
Alder 18 til 100 · Alle køn · Opdateret 1. okt. 2026 · NCT05268289

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

RekruttererFase 2
  • The University of Texas Health Science Center at Houston, Houston
Alder 18 til 74 · Alle køn · Opdateret 1. okt. 2026 · NCT07409181

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

RekruttererFase 3
  • Novel Research LLC, Bellaire · 7 mi væk
Alder 12 til 100 · Alle køn · Opdateret 1. okt. 2026 · NCT06133972

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

RekruttererFase 3
  • Research Site, Houston
Alder 5 til 17 · Alle køn · Opdateret 30. sep. 2026 · NCT05835310

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

RekruttererFase 3
  • Research Site, Houston
Alder 18 til 70 · Alle køn · Opdateret 25. sep. 2026 · NCT07430306

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

RekruttererFase 1
  • UT MD Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT03816345

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

RekruttererFase 1
  • Baylor College of Medicine, Houston
Alder 18 til 60 · Alle køn · Opdateret 14. sep. 2026 · NCT06975787

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

RekruttererFase 3
  • Accurate Clinical Research, Humble · 17 mi væk
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT07355218

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

RekruttererFase 1/2
  • University of Texas MD Anderson Cancer Center, Houston
Alder 18 til 65 · Alle køn · Opdateret 26. aug. 2026 · NCT06121297

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

RekruttererFase 3
  • Novel Research, LLC., Houston
  • Northwest Houston Arthritis, Houston
  • Rheumatology Care Center, PLLC, Bellaire · 7 mi væk
Alder 18 til 75 · Alle køn · Opdateret 30. jul. 2026 · NCT07201129

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

RekruttererObservationsstudie
  • M D Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 20. maj 2026 · NCT04751396

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

RekruttererFase 1/2
  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
Alder 18 og opefter · Alle køn · Opdateret 15. apr. 2026 · NCT06434363

Lupus forsøg i andre byer

Andre studier i Houston

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.